Jacobs Levy Equity Management Inc. Takes Position in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Jacobs Levy Equity Management Inc. acquired a new stake in Alnylam Pharmaceuticals worth approximately $41.3 million, purchasing 152,970 shares during the 1st quarter of 2023.
• Recent upgrades and price target boosts from analysts have resulted in a consensus target price of $417.38 for Alnylam Pharmaceuticals, with 22 analysts rating the stock as a Buy.
• CEO Yvonne Greenstreet and Director Dennis A. Ausiello recently sold shares of Alnylam Pharmaceuticals, with insiders offloading a total of 57,594 shares in the last three months.

Jacobs Levy Equity Management Inc. bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 152,970 shares of the biopharmaceutical company's stock, valued at approximately $41,305,000. Jacobs Levy Equity Management Inc. owned approximately 0.12% of Alnylam Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ALNY. SVB Wealth LLC bought a new position in Alnylam Pharmaceuticals during the first quarter worth about $27,000. Park Square Financial Group LLC acquired a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $28,000. Whipplewood Advisors LLC increased its position in shares of Alnylam Pharmaceuticals by 208.8% during the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 71 shares during the last quarter. Bessemer Group Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 176.9% during the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock worth $29,000 after acquiring an additional 69 shares during the last quarter. Finally, Colonial Trust Co SC acquired a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $35,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 1,396 shares of the business's stock in a transaction on Monday, August 18th. The stock was sold at an average price of $453.27, for a total value of $632,764.92. Following the sale, the executive vice president directly owned 22,719 shares in the company, valued at $10,297,841.13. The trade was a 5.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Pushkal Garg sold 1,455 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $458.41, for a total value of $666,986.55. Following the completion of the transaction, the executive vice president owned 20,221 shares of the company's stock, valued at approximately $9,269,508.61. This trade represents a 6.71% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 57,594 shares of company stock valued at $25,551,456 in the last ninety days. 1.50% of the stock is owned by corporate insiders.

Alnylam Pharmaceuticals Stock Down 0.1%

NASDAQ:ALNY traded down $0.61 on Thursday, hitting $468.70. The stock had a trading volume of 249,265 shares, compared to its average volume of 972,394. The business's fifty day moving average is $396.04 and its 200 day moving average is $313.80. The company has a market cap of $61.44 billion, a PE ratio of -189.68 and a beta of 0.32. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $484.21.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating analysts' consensus estimates of ($0.54) by $0.86. The company had revenue of $773.69 million for the quarter, compared to analyst estimates of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The company's revenue for the quarter was up 17.3% on a year-over-year basis. During the same quarter last year, the company earned ($0.13) earnings per share. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Needham & Company LLC boosted their target price on Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the stock a "buy" rating in a report on Thursday, July 31st. Jefferies Financial Group upped their target price on Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the company a "buy" rating in a research report on Monday, July 7th. Chardan Capital upped their price objective on Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. JPMorgan Chase & Co. upped their target price on Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the stock an "overweight" rating in a report on Wednesday, August 6th. Finally, Scotiabank increased their price target on Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the company a "sector outperform" rating in a research note on Friday, August 1st. Twenty-three research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $421.28.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.